Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27566333 | 0.83 | CYP2D6 (0.50) | TAAR1SSTR4L3MBTL1CXCR4CYP2D6 | |
| SCHEMBL1206770 | 0.82 | SSTR4 (0.42) | TAAR1SSTR4CXCR4HTR1ANAMPT | |
| SCHEMBL1206318 | 0.81 | CXCR4 (0.41) | TAAR1SSTR4CXCR4HTR1AFDPS | |
| SCHEMBL1206521 | 0.80 | HDAC3 (0.47) | TAAR1SSTR4CXCR4CYP2D6TSHR | |
| SCHEMBL17145110 | 0.80 | SSTR4 (0.38) | TAAR1SSTR4CXCR4HTR1AFDPS | |
| SCHEMBL13382331 | 0.80 | TAAR1 (0.42) | TAAR1L3MBTL1CXCR4HTR1AFDPS | |
| SCHEMBL23928449 | 0.79 | TAAR1 (0.53) | TAAR1CXCR4HTR1AFDPSTBXAS1 | |
| SCHEMBL27585984 | 0.79 | ADRA2A (0.51) | TAAR1SSTR4HTR1ACYP2D6 | |
| SCHEMBL1204960 | 0.79 | KDM4E (0.46) | SSTR4CXCR4 | |
| SCHEMBL1204486 | 0.78 | NR1D1 (0.45) | L3MBTL1CXCR4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827597-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827597-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827597-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230097144-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230097144-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-11572360-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572360-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | INNATE TUMOR IMMUNITY, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210332040-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY INC (US) | 2021-10-28 | — | — | US | disclosed |
| WO-2020037094-A1 | SUBSTITUED 4-AMINO-1H-IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097144-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | NLRP3, NOD1, NLRP1 | TAAR1 3273/4885SSTR4 3336/4885L3MBTL1 3341/4885 |
| US-11827597-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | NLRP3, NOD1, NLRP1 | TAAR1 3273/4885SSTR4 3336/4885L3MBTL1 3341/4885 |
| US-11572360-B2 | Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | NLRP3, NOD1, NLRP1 | TAAR1 3273/4885SSTR4 3336/4885L3MBTL1 3341/4885 |
| US-20210332040-A1 | SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | NLRP3, NOD1, NLRP1 | TAAR1 3273/4885SSTR4 3336/4885L3MBTL1 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.